Big drugmakers, searching for new sources of revenue, are paying hefty premiums for biotechnology businesses, with two multibillion-dollar acquisitions just announced in the last 10 days (14 January 2018 to 25 January 2018). Sanofiwill buy hemophilia drugmaker Bioverativ for $11.6 billion, a 63% premium, as the French drugmaker braces for generic-drug companies to launch lower-priced versions of Lantus insulin, its best-seller. And Celgene's cash deal to buy Juno Therapeutics values shares in the biotech company at $9 billion, 87% more than last week.
The above news stories illustrate two key points of strategy: 1) the rise of open innovation, as big pharma companies increasingly buy new biotech drugs rather than develop them in-house; 2) the imperative of maintaining growth growth at all costs using acquisitions as one route.
Identify 2 pros and 2 cons specific to the above two acquisition stories. with brief explanation
Clearly number in your post the 2 pros and 2 cons. Be specific in your answers.